Basic Search
|
Summaries
|
Advanced SearchViolation Tracker Individual Record
Company: Merck
Current Parent Company:
Merck
Parent at the Time of the Penalty Announcement:
subscribe to see this data field
Penalty: $56,000,000
Year: 2023
Date: October 18, 2023
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal:
Generic Drug Pay for Delay
Violation Description: Merck agreed to pay $56 million to end-payor plaintiffs to settle litigation alleging it and Glenmark Pharmaceuticals conspired to delay the launch of a generic version of the cholesterol drug Zetia.
Level of Government: federal
Action Type: private litigation
Court: Eastern District of Virginia
Civil or Criminal Case: civil
Case ID: 2:18-md-02836
Case Name: In Re: Zetia (Ezetimibe) Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: New Jersey
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data:
(click here)
Link to PACER Case Docket (must be logged in):
(click here)
Link to Archived Court Document:
subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker
Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the
Update Log.